Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sildenafil + l-arginine is a **combination drug** used primarily for the treatment of erectile dysfunction and for improvement of blood circulation. Sildenafil is a **phosphodiesterase type 5 (PDE5) inhibitor** that prevents the breakdown of cyclic guanosine monophosphate (cGMP), thus enhancing and prolonging nitric oxide-mediated vasodilation. L-arginine is a natural amino acid and the **biological precursor of nitric oxide**, which further augments cGMP pathway activity by increasing nitric oxide production, relaxing vascular smooth muscle, and improving endothelial function. Their combined use leads to additive or synergistic vasodilatory effects that enhance erectile function and may allow effective treatment with lower doses of each drug. Clinical and preclinical studies demonstrate improved efficacy for erectile dysfunction with the combination versus sildenafil alone, and confirm a favorable safety profile. Other possible applications (with clinical supervision) include support of cardiovascular function and improvement of coronary blood flow in specific surgical contexts[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sildenafil + l-arginine.